FIRST WAVE BIOPHARMA, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.96 USD | +4.59% |
|
+6.47% | -29.52% |
| May. 10 | First Wave BioPharma, Inc. announced a financing transaction | CI |
| Mar. 29 | First Wave BioPharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Presenter SpeechUnknown Analyst (Analysts)Welcome to the 7th Emerging Growth Conference. I am ...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
First Wave BioPharma, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the research and development of targeted, non-systemic therapies for the treatment of patients with gastrointestinal (GI) diseases. It is focused on developing a therapeutic pipeline with multiple late-stage clinical programs built around three proprietary technologies: Latiglutenase, a targeted oral biotherapeutic for celiac disease designed to breakdown gluten into non-immunogenic peptides; the biologic Adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency, and Capeserod, a selective 5-HT4 receptor partial agonist which the Company is developing as a gastroparesis therapeutic.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
2.83
USD
Average target price
36
USD
Spread / Average Target
+1,172.08%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -29.52% | 5.73M | |
| +33.37% | 49.46B | |
| +1.55% | 42.58B | |
| +49.11% | 42.49B | |
| -4.22% | 29.09B | |
| +11.57% | 26.61B | |
| -21.00% | 18.64B | |
| +7.36% | 13.16B | |
| +28.30% | 12.55B | |
| +23.80% | 12.1B |
- Stock Market
- Equities
- FWBI Stock
- News First Wave BioPharma, Inc.
- Transcript : AzurRx BioPharma, Inc. Presents at 7th Emerging Growth Conference, May-12-2021 10